Web Images Videos Maps News Shopping Gmail more »
Sign in
Scholar Home  
  Advanced Scholar Search
Scholar Preferences
Scholar Results 1 - 10 of about 101 related to Sarker: Severe hypo-α-lipoproteinemia during treatment with rosiglitazone. (0.11 sec) 

Severe hypo-α-lipoproteinemia during treatment with rosiglitazone


A Sarker, RK Semple, SF Dinneen, SO'Rahilly, … - Diabetes care, 2004 - Am Diabetes Assoc
Thiazolidinedione drugs are in widespread use for the treatment of type 2
diabetes. In addition to improving insulin sensitivity, they generally result in
a modest elevation of plasma HDL cholesterol. We report three patients, all ...
Cited by 15 - Related articles - BL Direct - All 7 versions

[CITATION] Paradoxical lowering of high-density lipoprotein cholesterol level in 2 patients receiving …


Z Ebcioglu, J Morgan, C Carey, D Capuzzi - Annals of internal medicine, 2003 - ncbi.nlm.nih.gov
1: Ann Intern Med. 2003 Nov 4;139(9):W80. Paradoxical lowering of high-density
lipoprotein cholesterol level in 2 patients receiving ...
Cited by 12 - Related articles - All 2 versions

Metabolism of apolipoproteins AI and AII in a patient with paradoxical reduction in high- …


L Beghin, N Capps, N Duhal, J Davies, B … - Annals of clinical biochemistry, 1999 - cat.inist.fr
Metabolism of apolipoproteins AI and AII in a patient with paradoxical
reduction in high-density lipoprotein due to ciprofibrate. ...
Cited by 11 - Related articles - BL Direct - All 2 versions

Paradoxically decreased HDL-cholesterol levels associated with rosiglitazone therapy


LM Gutschi, JC Malcolm, CM Favreau, TC Ooi - ANNALS OF PHARMACOTHERAPY, 2006 - Harvey Whitney Books
Type 2 diabetes is a disorder characterized by insulin re- sistance with the
associated metabolic consequences of hyperglycemia, diabetic dyslipidemia,
hypertension, and hypercoagulability.1 These metabolic abnormalities ...
Cited by 12 - Related articles - BL Direct - All 4 versions

[CITATION] Severe decrease in serum HDL-cholesterol during combination therapy of bezafibrate and …


H Senba, M Kawano, M Kawakami - Journal of atherosclerosis and thrombosis, 2006 - sciencelinks.jp
Cited by 8 - Related articles - Cached - BL Direct - All 2 versions

Combination therapy with fenofibrate and rosiglitazone paradoxically lowers serum HDL …

- diabetesjournals.org [PDF] 
L Normén, J Frohlich, J Montaner, M Harris, T … - Diabetes Care, 2004 - Am Diabetes Assoc
Thiazolidinediones (TZDs) are insu- lin sensitizers widely used in the treatment
of type 2 diabetes (1). Fi- brates are lipid-lowering drugs that lower
triglycerides (TGs) and increase HDL cholesterol (2). Individually, ...
Cited by 22 - Related articles - BL Direct - All 7 versions

Paradoxical HDL-C reduction during rosiglitazone and fibrate treatment


C Shetty, M Balasubramani, N Capps, J … - Diabetic Medicine, 2007 - interscience.wiley.com
It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ...
Cited by 8 - Related articles - BL Direct - All 5 versions

Thiazolidinediones and lowered HDL cholesterol


RL Savage, A Kiuru - Diabetes care, 2005 - Am Diabetes Assoc
These series of cases include only one case of HDL cholesterol lowering in a
patient taking rosiglitazone without a fibrate (1). There are no published case
reports of this reaction occurring with other thiazolidinediones, where the ...
Cited by 4 - Related articles - BL Direct - All 5 versions

High incidence of reduced plasma HDL cholesterol in diabetic patients treated with …


S Keidar, H Guttmann, T Stam, I Fishman, C … - Pharmacoepidemiology and Drug Safety, 2007 - interscience.wiley.com
It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ...
Cited by 5 - Related articles - BL Direct - All 4 versions

Paradoxical high-density lipoprotein reduction induced by fenofibrate and ciprofibrate


PO Collinson, CJ Hjelm, R Canepa-Anson - Annals of clinical biochemistry, 1996 - cat.inist.fr
Paradoxical high-density lipoprotein reduction induced by fenofibrate and
ciprofibrate. PO COLLINSON, CJ HJELM, R CANEPA-ANSON Annals ...
Cited by 13 - Related articles - BL Direct - All 2 versions


Result Page: 

1

2

3

4

5

6

7

8

9

10

Next


 


Go to Google Home - About Google - About Google Scholar

©2009 Google